Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MT-6402 |
Synonyms | |
Therapy Description |
MT-6402 is an engineered toxin body that targets CD274 (PD-L1), potentially leading to killing of tumor cells expressing CD274 (PD-L1) and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr CT152). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MT-6402 | MT 6402|MT6402 | PD-L1 Inhibitor 14 | MT-6402 is an engineered toxin body that targets CD274 (PD-L1), potentially leading to killing of tumor cells expressing CD274 (PD-L1) and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr CT152). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | MT-6402 | Case Reports/Case Series | Actionable | In a Phase I trial, MT-6402 treatment led to an antitumor immune response and decreased metastatic bone lesions in a CD274 (PD-L1)-positive non-small cell lung cancer patient with osseous metastases (Cancer Res 2022;82(12_Suppl):Abstract nr CT152). | detail... |
CD274 positive | Advanced Solid Tumor | predicted - resistant | MT-6402 | Preclinical - Cell culture | Actionable | In a preclinical study, MT-6402 treatment demonstrated cytotoxicity in a panel of CD274 (PD-L1)-positive cancer cell lines in culture (Cancer Res 2022;82(12_Suppl):Abstract nr CT152). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04795713 | Phase I | MT-6402 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | Terminated | USA | 0 |